Table 1: Distribution of HPV types at admission and every three months of followup according to clinical outcome of women with CIN 2.

Clinical outcomeAdmissionFollow-up visit (month)Possibly causal HPV
3rd6th9th12th

Regression at 3rd7171, 58NaNeg16Undefined

Regression at 6th16, 58161616Na58
5151NegNegNeg51
26NaNegNa1626
39, 52, 54, 56, 6839, 52, 6852, 5158Na39
1616161616Undefined
31313131NegUndefined
NegNegNegNeg16Undefined
16, 56, 6656, 33Na33Na56
Neg1658NegNaUndefined
31Na61NaNaUndefined

Regression at 9th3333, 16, 5833NegNeg33
16, 67Na67Neg1667
1616, 39NegNegNeg16
6, 16, 3333NegNegNeg33
39, 51, 53, 56Na39, 5153, 1839, 5951

Regression at 12thNegNaNegNa16, 58, 59Undefined
1616NaNa16Undefined

Persistence as CIN 11616Na16, 61, 8116, 61, 8116
NegNeg535353, 16, 42Undefined
161616NegNaUndefined
81518116NaUndefined

Persistence as CIN 233NaNaNa3333
16, 5816, 5816, 5816, 5816, 5816 or 58
16, 5816, 5816, 5816, 58Na16 or 58
35, 58, 73Neg35, 58, 6235, 58, 16Na35 or 58

Progression at 6th16161616Na16
16161616, 6616, 6616
16, 33, 6816, 33, 6816, 3316, 3316, 33, 6816 or 33

Progression at 9th16, 68, 8416, 84, 42, 5816, 68, 5816, 68, 5816, 1816

Progression at 12th393939393939
16, 51, 52, 5316, 52, 45, 8416, 52, 8416, 52, 5816, 5216 or 52
16, 52NaNa16, 5216, 5216 or 52
52, 8252, 8252Na5252
66, 3939NaNaUndefined
313131NaNa31
16, 5616, 56, 7316, 56, 73NaNa16 or 56

New HPV types detected during followup are underlined.